Planned intervention: On Wednesday April 3rd 05:30 UTC Zenodo will be unavailable for up to 2-10 minutes to perform a storage cluster upgrade.
Published April 17, 2013 | Version v1
Journal article Restricted

The synthesis and pharmacological evaluation of adamantane-derived indoles: Cannabimimetic drugs of abuse.

  • 1. School of Chemistry, The University of Sydney, NSW 2006, Australia and Brain and Mind Research Institute, NSW 2050, Australia
  • 2. School of Chemistry, The University of Sydney, NSW 2006, Australia
  • 3. The Australian School of Advanced Medicine, Macquarie University, NSW 2109, Australia
  • 4. School of Psychology, The University of Sydney, NSW 2006, Australia
  • 5. Australian Sports Drug Testing Laboratory, National Measurement Institute, NSW 2073, Australia
  • 6. Faculty of Pharmacy, The University of Sydney, NSW 2006, Australia
  • 7. School of Medical Sciences, The University of Auckland, Auckland 1142, New Zealand
  • 8. School of Chemistry, The University of Sydney, NSW 2006, Australia; Brain and Mind Research Institute, NSW 2050, Australia and Discipline of Medical Radiation Sciences, The University of Sydney, NSW 2006, Australia

Description

Two novel adamantane derivatives, adamantan-1-yl(1-pentyl-1H-indol-3-yl)methanone (AB-001) and N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide (SDB-001), were recently identified as cannabimimetic indoles of abuse. Conflicting anecdotal reports of the psychoactivity of AB-001 in humans, and a complete dearth of information about the bioactivity of SDB-001, prompted the preparation of AB-001, SDB-001, and several analogues intended to explore preliminary structure-activity relationships within this class. This study sought to elucidate which structural features of AB-001, SDB-001, and their analogues govern the cannabimimetic potency of these chemotypes in vitro and in vivo. All compounds showed similar full agonist profiles at CB1 (EC50 = 16-43 nM) and CB2 (EC50 = 29-216 nM) receptors in vitro using a FLIPR membrane potential assay, with the exception of SDB-002, which demonstrated partial agonist activity at CB2 receptors. The activity of AB-001, AB-002, and SDB-001 in rats was compared to that of Δ(9)-tetrahydrocannabinol (Δ(9)-THC) and cannabimimetic indole JWH-018 using biotelemetry. SDB-001 dose-dependently induced hypothermia and reduced heart rate (maximal dose 10 mg/kg) with potency comparable to that of Δ(9)-tetrahydrocannabinol (Δ(9)-THC, maximal dose 10 mg/kg), and lower than that of JWH-018 (maximal dose 3 mg/kg). Additionally, the changes in body temperature and heart rate affected by SDB-001 are of longer duration than those of Δ(9)-THC or JWH-018, suggesting a different pharmacokinetic profile. In contrast, AB-001, and its homologue, AB-002, did not produce significant hypothermic and bradycardic effects, even at relatively higher doses (up to 30 mg/kg), indicating greatly reduced potency compared to Δ(9)-THC, JWH-018, and SDB-001.

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.

Additional details

Funding

INMIND – Imaging of Neuroinflammation in Neurodegenerative Diseases 278850
European Commission